CDT: CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for CDT
Across the 14 sessions after earlier CDT headlines, the stock closed higher 6 times and lower 8 times, with a median move of 8.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CDT | SPY |
|---|---|---|---|
| May 7, 2026 | CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market | -8.0% | -0.3% |
| May 6, 2026 | CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions | +8.7% | +1.4% |
| Apr 16, 2026 | CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery | -24.4% | +0.2% |
| Apr 7, 2026 | CDT Notes Sarborg Publication of PRISM Framework Expanding AI | +6.8% | +0.0% |
| Mar 26, 2026 | CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings | -9.6% | -1.8% |
| Mar 25, 2026 | CDT Equity Inc. Announces Reverse Stock Split | -12.0% | +0.6% |
Quantisnow market dataNASDAQ
CDT
CDT Equity Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Get push alerts for CDT
Full CDT profile on Quantisnow Follow CDT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time